The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2025 | The clinical journey of belantamab mafodotin for myeloma and lessons learned in its development
Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the evolving role of belantamab mafodotin (belamaf) in the treatment landscape of multiple myeloma (MM), reflecting on the agent’s clinical journey and emphasizing the significance of modified dosing schedules. Prof. Lonial notes that extended dosing intervals and combining belamaf with other agents can enhance efficacy while mitigating toxicity, including ocular side effects. He underscores the importance of clinician confidence in using less frequent dosing as part of future clinical practice. This interview took place at the 11th World Congress on Controversies in Multiple Myeloma (COMy) congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
You know, belamaf is a really interesting agent and even five years ago when we first had FDA approval, we knew there were some patients who just had really, really long remissions with limited dosing. And what I think we’ve learned with the approval, then unapproval, and what we hope will be the re-approval in the coming year, and I know in the UK it is re-approved, is the idea that less frequent dosing in partnership with other drugs, A, reduces toxicity, but B, seems to improve efficacy...
You know, belamaf is a really interesting agent and even five years ago when we first had FDA approval, we knew there were some patients who just had really, really long remissions with limited dosing. And what I think we’ve learned with the approval, then unapproval, and what we hope will be the re-approval in the coming year, and I know in the UK it is re-approved, is the idea that less frequent dosing in partnership with other drugs, A, reduces toxicity, but B, seems to improve efficacy. The dosing of every 8 to 12 weeks really shows profound efficacy in partnership with either bortezomib or pomalidomide. And I think that this portends really good use of this agent down the road. And we as a community need to get comfortable with less frequent dosing and not be worried that we’re going to underdose patients. I’m not sure you can underdose patients, particularly if you’re protecting and reducing the ocular side effects, which we know are an issue with the every three-week dosing with belamaf.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
